Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab plus FOLFIRI vs FOLFIRI in previously treated metastatic colorectal cancer
2005-004676-20Phase 3Completed
- Sponsor
- Amgen
- Start
- Mar 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of panitumumab in metastatic colon cancer (mCRC), Colon adenocarcinoma and rectal adenocarcinoma (2 arms), sponsored by Amgen. Primary endpoints: Overall survival and Progression-free survival. Started Mar 2006; status: completed.
02
Drugs
panitumumab
03
Conditions
metastatic colon cancer (mCRC)Colon adenocarcinomarectal adenocarcinoma
Beyond the preview
Go deeper on 2005-004676-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004676-20.